Tag Archives: Deal

Roche Unsweetens Genentech Pot and Takes it to the Shareholders

By George Koroneos | Published: January 30, 2009
Image by Getty Images via Daylife Roche wants Genentech and it’s sick of waiting for a deal. Six months after a special committee for the biotech firm’s board of directors rejected Roche’s offer of $43.7 billion or $89 a share, Roche has switched gears and dropped the offer to $86.50 per share and is taking negotiations to [...]
Posted in Deals | Also tagged , , , , | 1 Comment

Lilly Puts Up $6.5 Billion for ImClone

By George Koroneos | Published: October 6, 2008
Lilly broke the news Monday morning that ImClone had accepted its offer to acquire the biotech firm for $6.5 billion or $70 per share—Lilly’s largest acquisition ever. With this purchase Lilly gains control of ImClone’s blockbuster, targeted cancer agent Erbitux, which is marketed for second- and third-line colon cancer and refractory head and neck cancer. ImClone also [...]
Posted in Biotech, Deals | Also tagged , , , , , , , | 1 Comment

King Ups Alpharma Offer

By George Koroneos | Published: September 11, 2008
King Pharmaceuticals sweetened its offer to purchase Alpharma this morning. The drug firm boosted the bid price to $37 per share or $1.6 billion from the initial of $33 a share it presented in early August. If Alpharma refuses, King is prepared to get down and dirty. In a pointed letter to Alpharma’s board, King President [...]
Posted in Deals | Also tagged , , , , , | Leave a comment

Icahn to BMS: Offer is Inadequate

By George Koroneos | Published: September 10, 2008
In a statement to the press today, ImClone Chairman Carl Icahn said that the review committee overlooking Bristol-Myers Squibb’s offer to purchase the biotech company for $60 per share $4.5 billion just isn’t good enough. He not only accused BMS of lowballing, but also admitted that the company has been in talks with the head of [...]
Posted in Biotech, Deals, Strategy | Also tagged , , , , , , , | 1 Comment